As of 2020, there are 3 FDA-approved therapies now available to the NMOSD community. The Sumaira Foundation for NMO is please to share the first-of-its-kind, NMOSD Therapies Chart.
Our goal in laying out these new and available therapies side-by-side is to empower the patient community to discuss their treatment options with their doctors to make informed decisions about their best paths forward. At TSF, we’re strong advocates for shared-decision making between patients and their physicians, especially when it comes to deciding what long-term treatment(s) to opt for.
This chart has been created by TSF. Our foundation works with all three pharmaceutical companies equally with an unbiased and objective lens.
Special thanks to Dr. Michael Levy (subject-matter expert), Andrea Sydney (volunteer project manager), and 3Dcubed (animator) for their support in bringing this chart to fruition.
Legend:
– Animated video for explanation
– Definition in text and audio format
 Soliris® (eculizumab) |  Uplizna™ (inebulizumab-cdon) |  Enspryng® (satralizumab) | |
| Pharmacology | Complement Inhibitor | B Cell Depletion | Interleuken-6 (IL-6) Inhibitor |
| Drug Delivery Method | Infusion (35 minutes) | Infusion (90 minutes) | Subcutaneous Injection |
| Frequency | Every 2 weeks | Every 6 months | Every 4 weeks |
| Dosage | 1200 mg | 300 mg | 120 mg |
| Reduction in Relapse Risk | 94% | 77% *monotherapy without background therapy | 79% with background therapy, 74% without background therapy |
| Antibody Criteria | AQP4+ NMOSD (MOG untested) | AQP4+ NMOSD (MOG untested) | AQP4+ NMOSD (MOG untested) |
| Common Side Effects | Headaches Runny Nose | Urinary Tract Infection Joint Pain | Headaches Runny Nose |
| Potential Serious Side Effects | Meningococcus Meningitis BLACK BOX WARNING: Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris and may become rapidly life-threatening or fatal if not recognized and treated early. Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) | Infusion reactions and infection | Infusion reactions and infection |
| Vaccinations | Meningococcus, infusion reactions and infections | none | None |
| Manufacturer |  |  |  |
| Patient Assistance Programs (including co-pay) | Alexion | Viela VIPS | Enspryng Co-Pay Program |
| Prescribing Information | Soliris ® Prescribing Information | Uplizna™ Prescribing Information | Enspryng™ Prescribing Information |